CVS Health Corp. stock gains on UBS buy rating and raised revenue outlook

CVS Health Corp. stock is trading near the upper end of its recent range after UBS reiterated a buy rating and the company raised its full-year revenue and earnings guidance following a strong second quarter.

CVS Health Corp. stock (ISIN US1266501006) is trading close to the upper end of its recent range, with the last closing price at 97.23 USD on September 2, 2026 according to MarketScreener, while UBS highlighted a positive stance on the shares published on September 3, 2026.

UBS buy stance underpins sentiment

According to a MarketScreener summary of UBS research dated September 3, 2026, UBS maintains a buy recommendation on CVS Health Corp. with an average price objective reported alongside the latest data, while the stock closed at 97.23 USD on September 2, 2026 and showed a modest decline of 0.38% that day.

The same data overview indicates a pre-market indication at 96.58 USD on September 3, 2026, implying that the shares are trading slightly below the latest closing level but still near the top of the recent price range, while broader coverage points to a 12?month share price increase of 31.1% versus 10.8% for the industry according to Zacks.

Revenue growth and guidance raise after Q2

A recent overview of the company’s performance compiled by Pluang reports that CVS Health delivered a 7.3% year?on?year revenue increase in the second quarter of 2026 to 106.1 billion USD.

In the same Q2 2026 context, the company raised its full?year revenue forecast to at least 414 billion USD, marking a higher target compared with its previous outlook, and also improved its earnings per share guidance according to this summary, which investors interpret as a signal of confidence in underlying operations.

The quantified growth of 7.3% in Q2 2026 revenue to 106.1 billion USD coupled with the higher full?year target of at least 414 billion USD suggests that CVS Health is expecting momentum to carry through the second half of the year, and that management sees scope for deleveraging supported by an improving balance sheet, a point also highlighted in the analysis by Zacks.

Pharmacy and health services as revenue driver

CVS Health Corp. operates a broad portfolio that includes retail pharmacies, pharmacy benefit management services, and health insurance offerings, and the Q2 2026 revenue of 106.1 billion USD indicates that these combined segments are sustaining large?scale top?line growth according to the performance summary referenced above.

One current operational topic is the company’s entry into the biosimilar space through its Cordavis unit, with Drug Channels reporting in September 2026 that Cordavis labeled Pyzchiva received no Part D coverage, underlining both the potential and the complexity of new product launches in the US reimbursement environment as noted by Drug Channels.

CVS Health retail and digital offering

A representative consumer?facing product angle for CVS Health Corp. is its extensive network of retail pharmacies combined with digital prescription services, which together form a key point of interaction with customers across the United States and contribute to the company’s large revenue base that reached 106.1 billion USD in Q2 2026.

Stock level and investor perspective

CVS Health Corp. stock is primarily listed on the New York Stock Exchange under the ticker CVS, and based on MarketScreener data the last closing price of 97.23 USD on September 2, 2026 keeps the shares below typical large?cap US healthcare peers trading at triple?digit levels but still reflects the 31.1% share price gain over the past year noted by Zacks, which compares with 10.8% for the broader healthcare industry and highlights the relative outperformance.

Key data on CVS Health Corp. stock

• Company: CVS Health Corp.
• ISIN: US1266501006
• Ticker: CVS
• Trading venue: NYSE
• Price (as of September 2, 2026): 97.23 USD
• Sector / Industry: Healthcare / Health services
• Index membership: S&P 500